{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:11:03Z","timestamp":1790878263281,"version":"4.1.0"},"reference-count":46,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Checkpoint inhibitors targeting PD-1 have shown unprecedented efficacy in some patients with cancer; however, coexpression of the immune checkpoint LAG-3 by tumor-infiltrating lymphocytes (TILs) might hinder such efficacy. PD-1 and LAG-3 are established markers of T-cell exhaustion in cancer and are coexpressed by stem-like CD8 T cells, a population critical for the response to anti\u2013PD-1 therapy, providing the rationale for their dual blockade. Yet, blocking LAG-3 can lead to the expansion of regulatory T cells (Treg), reducing the efficacy of anti\u2013LAG-3 therapy on CD8 TILs. To address this limitation, we developed tobemstomig, a novel bispecific antibody (BsAb) to preferentially and simultaneously block PD-1 and LAG-3 in cis on tumor-specific CD8 TILs while sparing Tregs. It provided superior tumor growth inhibition in mouse models by replenishing stem-like cells and cytotoxic effector CD8 TILs, resulting in durable responses compared with monospecific antibodies targeting PD-1 and LAG-3 separately, which eroded the stem-like T-cell pool over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Constitutive LAG-3 expression on Tregs may limit anti\u2013LAG-3 therapy efficacy by promoting Treg expansion, leading to suppression of tumor-specific CD8 T-cell responses. Tobemstomig, a BsAb preferentially targeting CD8, expands tumor-specific stem-like CD8 TILs and reduces intratumoral Tregs, resulting in superior, durable tumor inhibition in mice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0207","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T20:20:32Z","timestamp":1781295632000},"page":"1619-1639","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8658-6590","authenticated-orcid":false,"given":"Patrick A.A.","family":"Weber","sequence":"first","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1375-8155","authenticated-orcid":false,"given":"Mario","family":"Perro","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-7849","authenticated-orcid":false,"given":"Valeria G.","family":"Nicolini","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-8195","authenticated-orcid":false,"given":"Klas","family":"Hatje","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-7808","authenticated-orcid":false,"given":"Silvia","family":"Jenni","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1266-4384","authenticated-orcid":false,"given":"Stefanie","family":"Briner","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0433-5699","authenticated-orcid":false,"given":"Esther","family":"Bommer","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0826-315X","authenticated-orcid":false,"given":"Manuela","family":"Tanner","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2131-9285","authenticated-orcid":false,"given":"Sylvain","family":"Pilet","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-8852","authenticated-orcid":false,"given":"Tamara","family":"H\u00fcsser","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-2690","authenticated-orcid":false,"given":"Emilio","family":"Y\u00e1ng\u00fcez","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5710-427X","authenticated-orcid":false,"given":"Stanford","family":"Chen","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9493-1954","authenticated-orcid":false,"given":"Antonio","family":"Peixoto","sequence":"additional","affiliation":[{"name":"3Pharmacology and Structural Biology, Toulouse University, CNRS, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5254-1554","authenticated-orcid":false,"given":"Iryna","family":"Dekhtiarenko","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0816-687X","authenticated-orcid":false,"given":"Laura","family":"Lauener","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2446-696X","authenticated-orcid":false,"given":"Sylvia","family":"Herter","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8178-1556","authenticated-orcid":false,"given":"Thomas","family":"Hofer","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-0742","authenticated-orcid":false,"given":"Carina","family":"Hage","sequence":"additional","affiliation":[{"name":"4Roche Innovation Center Munich, Penzberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1936-2277","authenticated-orcid":false,"given":"Meher","family":"Majety","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0581-9579","authenticated-orcid":false,"given":"Marina","family":"Bacac","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-8600","authenticated-orcid":false,"given":"Sara","family":"Colombetti","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2818-2204","authenticated-orcid":false,"given":"Stephane","family":"Leclair","sequence":"additional","affiliation":[{"name":"4Roche Innovation Center Munich, Penzberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2703-4925","authenticated-orcid":false,"given":"Stefan","family":"Seeber","sequence":"additional","affiliation":[{"name":"4Roche Innovation Center Munich, Penzberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4649-2983","authenticated-orcid":false,"given":"Merlind","family":"M\u00fccke","sequence":"additional","affiliation":[{"name":"2Roche Innovation Center Basel, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8206-2771","authenticated-orcid":false,"given":"Pablo","family":"Uma\u00f1a","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-7280","authenticated-orcid":false,"given":"Christian","family":"Klein","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."},{"name":"5Department of Biochemistry, Faculty of Chemistry and Pharmacy, Ludwig Maximilians University of Munich, Munich, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9913-9285","authenticated-orcid":false,"given":"Laura","family":"Codarri Deak","sequence":"additional","affiliation":[{"name":"1Roche Innovation Center Zurich, Schlieren, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026070906011148100_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2026070906011148100_bib2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2026070906011148100_bib3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"2026070906011148100_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070906011148100_bib5","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","article-title":"Regulatory T cells in cancer","volume":"108","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"2026070906011148100_bib6","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"2026070906011148100_bib7","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"2026070906011148100_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"2026070906011148100_bib9","doi-asserted-by":"crossref","first-page":"eabe3702","DOI":"10.1126\/sciimmunol.abe3702","article-title":"Inhibitory signaling sustains a distinct early memory CD8+ T cell precursor that is resistant to DNA damage","volume":"6","author":"Johnnidis","year":"2021","journal-title":"Sci Immunol"},{"key":"2026070906011148100_bib10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","article-title":"Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells","volume":"212","author":"Odorizzi","year":"2015","journal-title":"J Exp Med"},{"key":"2026070906011148100_bib11","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1016\/j.cell.2024.07.018","article-title":"LAG-3 sustains TOX expression and regulates the CD94\/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity","volume":"187","author":"Ngiow","year":"2024","journal-title":"Cell"},{"key":"2026070906011148100_bib12","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"2026070906011148100_bib13","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"2026070906011148100_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"2026070906011148100_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.immuni.2019.11.002","article-title":"Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1+ stem-like CD8+ T cells during chronic infection","volume":"51","author":"Hudson","year":"2019","journal-title":"Immunity"},{"key":"2026070906011148100_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ni.2180","article-title":"Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection","volume":"13","author":"Butler","year":"2011","journal-title":"Nat Immunol"},{"key":"2026070906011148100_bib17","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"2026070906011148100_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41590-022-01210-5","article-title":"Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3","volume":"23","author":"Grebinoski","year":"2022","journal-title":"Nat Immunol"},{"key":"2026070906011148100_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"2026070906011148100_bib20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"2026070906011148100_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-019-1836-5","article-title":"An intra-tumoral niche maintains and differentiates stem-like CD8 T cells","volume":"576","author":"Jansen","year":"2019","journal-title":"Nature"},{"key":"2026070906011148100_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"2026070906011148100_bib23","doi-asserted-by":"crossref","first-page":"e0150084","DOI":"10.1371\/journal.pone.0150084","article-title":"Poxvirus-based active immunotherapy with PD-1 and LAG-3 dual immune checkpoint inhibition overcomes compensatory immune regulation, yielding complete tumor regression in mice","volume":"11","author":"Foy","year":"2016","journal-title":"PLoS One"},{"key":"2026070906011148100_bib24","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070906011148100_bib25","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","article-title":"Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors","volume":"3","author":"Thommen","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2026070906011148100_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070906011148100_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"key":"2026070906011148100_bib28","doi-asserted-by":"crossref","first-page":"e164809","DOI":"10.1172\/JCI164809","article-title":"Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma","volume":"133","author":"Huuhtanen","year":"2023","journal-title":"J Clin Invest"},{"key":"2026070906011148100_bib29","doi-asserted-by":"crossref","first-page":"eaah4569","DOI":"10.1126\/sciimmunol.aah4569","article-title":"LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes","volume":"2","author":"Zhang","year":"2017","journal-title":"Sci Immunol"},{"key":"2026070906011148100_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/protein\/gzy021","article-title":"Variable heavy-variable light domain and Fab-arm CrossMabs with charged residue exchanges to enforce correct light chain assembly","volume":"31","author":"Regula","year":"2018","journal-title":"Protein Eng Des Sel"},{"key":"2026070906011148100_bib31","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1101\/gr.271908.120","article-title":"Automated quality control and cell identification of droplet-based single-cell data using dropkick","volume":"31","author":"Heiser","year":"2021","journal-title":"Genome Res"},{"key":"2026070906011148100_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol"},{"key":"2026070906011148100_bib33","doi-asserted-by":"crossref","first-page":"lqab102","DOI":"10.1093\/nargab\/lqab102","article-title":"Besca, a single-cell transcriptomics analysis toolkit to accelerate translational research","volume":"3","author":"M\u00e4dler","year":"2021","journal-title":"NAR Genom Bioinform"},{"key":"2026070906011148100_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions","volume":"29","author":"Schlothauer","year":"2016","journal-title":"Protein Eng Des Sel"},{"key":"2026070906011148100_bib35","doi-asserted-by":"crossref","first-page":"aah3374","DOI":"10.1126\/science.aah3374","article-title":"Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"key":"2026070906011148100_bib36","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/eji.200939874","article-title":"Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4","volume":"40","author":"Woo","year":"2010","journal-title":"Eur J Immunol"},{"key":"2026070906011148100_bib37","doi-asserted-by":"crossref","first-page":"eaal3604","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026070906011148100_bib38","doi-asserted-by":"crossref","first-page":"e8662","DOI":"10.15252\/emmm.201708662","article-title":"Innovations, challenges, and minimal information for standardization of humanized mice","volume":"12","author":"Stripecke","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2026070906011148100_bib39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/CJI.0b013e3181fad2b0","article-title":"Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells","volume":"33","author":"Inozume","year":"2010","journal-title":"J Immunother"},{"key":"2026070906011148100_bib40","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8 tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest"},{"key":"2026070906011148100_bib41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"2026070906011148100_bib42","doi-asserted-by":"crossref","first-page":"e2418985122","DOI":"10.1073\/pnas.2418985122","article-title":"Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1","volume":"122","author":"Mok","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070906011148100_bib43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41586-025-09440-x","article-title":"Inhibitory PD-1 axis maintains high avidity stem-like CD8+ T cells","volume":"649","author":"Hor","year":"2026","journal-title":"Nature"},{"key":"2026070906011148100_bib44","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1158\/1078-0432.CCR-24-2499","article-title":"Unraveling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047","volume":"31","author":"Lipson","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026070906011148100_bib45","article-title":"A first-in-human phase 1 clinical trial evaluating clinical activity and proof-of-mechanism of tobemstomig, a PD1-LAG3 bispecific antibody, in patients with CPI-experienced melanoma","author":"Garralda","year":"2026  7","journal-title":"Cancer Res"},{"key":"2026070906011148100_bib46","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1038\/s41591-025-03967-2","article-title":"Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b\/2 Morpheus-Melanoma trial","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0207\/3803485\/crc-26-0207.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1619\/3810261\/crc-26-0207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1619\/3810261\/crc-26-0207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:01:23Z","timestamp":1783591283000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1619\/786394\/Tobemstomig-a-Novel-Bispecific-Antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0207","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.32947281","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947260","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947272","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947284","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947263","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947275","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947254","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947287","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947266","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947278","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947257","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.32947269","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8584791","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}